Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease
CARACIIM
1 other identifier
observational
100
1 country
1
Brief Summary
An unusual increase in cases of invasive meningococcal infection between late 2022 and early 2023. These cases sometimes had atypical presentations (large numbers of bacteremias without meningitis). The distribution of serogroups was also unusual in our center (large number of serotype Y meningococcal IMD). This development comes after three years marked by the Corona-Virus-Disease-19 pandemic, which led to a profound change in the behaviors involved in the transmission of infectious diseases. Barrier measures have considerably reduced the population's exposure to meningococcus, and may have encouraged a reduction in mucosal immunity to this pathogen. The end of 2022 was also marked by intense viral circulation (syncitial respiratory virus-influenza-COVID), which may have favored invasive forms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 30, 2023
CompletedFirst Submitted
Initial submission to the registry
July 20, 2023
CompletedFirst Posted
Study publicly available on registry
August 8, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2023
CompletedAugust 9, 2023
August 1, 2023
2 months
July 20, 2023
August 8, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Number of patient presenting with Invasive Meningococcal infection and its serogroup
\- Evolution of the Number of case according to time and the evolution of serogroup There will be two study period. The number of Invasive Meningococcal infection and their serogroup will be counted in each period.
Two period of 18month, one when facial mask were recommanded, and one after
Interventions
There is no intervention. Only retrieving clinical, biological and epidemiological data from patient files
Eligibility Criteria
Patient from the West part of France
You may qualify if:
- Clinical diagnosis of Invasive Meningococcal infection (defined by the isolation of Neisseria meningitis in a normaly steril site (CSL, blood, articulation, ..) by PCR or culture.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Poitiers University
Poitiers, Vienne, 86000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
France CAZENAVE ROBLOT, PhD
SPILF
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 20, 2023
First Posted
August 8, 2023
Study Start
June 30, 2023
Primary Completion
August 30, 2023
Study Completion
September 30, 2023
Last Updated
August 9, 2023
Record last verified: 2023-08